ClinicalTrials.gg
CompletedNCT03364335Updated Aug 21, 2019Results posted

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

A Phase 2 interventional study of Leu Sil 1.0mg and Leu Sil 4.0mg in Obesity, sponsored by NuSirt Biopharma. Completed at 15 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-08-21.

Sponsored by NuSirt Biopharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a 24-week study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. The primary objective of this study is to evaluate the percentage change in body weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24).

Read the detailed description

This is a randomized, 24-week, placebo-controlled, double-blind study to evaluate the effects of two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. Subjects meeting all the inclusion criteria and no exclusion criteria will be randomized to one of five study arms.

The primary objective of this study is to evaluate the percentage change in body weight in subjects from Baseline/Visit 2 (Day 1) to Study Termination/Visit 8 (Day 168/Week 24) receiving two fixed-dose combinations of leucine and sildenafil or two fixed-dose combinations of leucine, sildenafil and metformin compared to placebo. Secondary objectives will also assess changes in absolute body weight, percentage of patients with ≥5% body weight loss, change in waist circumference, change in HbA1c, change in fasting glucose, change in blood lipids such as cholesterol, LDL, HDL, triglycerides, change in blood pressure and changes in in C-reactive protein. In addition this study will evaluate the safety and tolerability of NS-0200 and NS-0300.

Patients will have one screening visits which will determine their eligibility based on lab tests. Once qualified, patients will be randomly assigned to either one of the treatment groups or the placebo control group and monitored for a total of 24 weeks. Patients will return to the clinic each month for lab tests, and routine examinations.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's enrollment of 267 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

NuSirt Biopharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 and ≤65 at study entry.
  2. Is male, or female and, if female, meets all of the following criteria:

    1. Not breastfeeding
    2. or negative serum pregnancy test result (human chorionic gonadotropin, beta subunit [β-hCG]) at Screening/Visit 1 (Day-7/Week-1) (not required for hysterectomized females)
    3. If of (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods [male condom with spermicide, with or without cervical cap or diaphragm], implants, injectables, oral contraceptives [must have been using for at least the last 3 months], some intrauterine contraceptive devices, tubal ligation, or in an established relationship with a vasectomized or same sex partner) during the entire duration of the study
  3. Stable body weight (±5%) and health over the last 3 months.
  4. Has a between 30 kg/m2 and 45 kg/m2
  5. Stable diet within the last three months
  6. Subjects on antidepressants, excluding those listed in the exclusion criteria, must have been on a stable dose regiment for at least 3 months prior to study enrollment and maintain stable dose during the study
  7. Clinical laboratory tests (hematology, clinical chemistry, and urinalysis) either normal, not or with abnormalities consistent with obesity
  8. Is able to read, understand, and sign the forms (ICF) and, when applicable, an authorization to use and disclose protected health information form (consistent with Health Insurance Portability and Accountability Act of 1996 [HIPAA] legislation), communicate with the investigator, and understand and comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of diabetes or on a diabetes medication
  2. ≥6.5% at Screening/Visit 1 (Day-7/Week-1)
  3. Severe renal impairment ( \< 45 mg/mL/1.73 m2) and/or patients with acute or chronic metabolic acidosis. Acidosis is defined as >25mmol/L computed without K.

    Normal is 8- 16, but acidosis is >25

  4. Use of any of the following medications in the eight weeks prior to entering screening for study participation and during the study:

    1. Use of any anti-diabetes medication including metformin and any combination drug that contains metformin
    2. Sildenafil
    3. Tadalafil
    4. Vardenafil
    5. OCT2/MATE inhibitors (e.g. cimetidine, quinidine, and pyrimethamine)
    6. Riociguat (guanylate cyclase stimulant)
    7. Alpha blockers
    8. Nitrates (e.g. oral nitrates, sublingual nitroglycerine and nitroglycerine patches)
    9. Potent inhibitors (e.g. clarithromycin, telithromycin, nefazodone, itraconazole, ketoconazole, atazanavir, darunavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir)
    10. All antihypertensive medications
    11. Medications associated with weight changes

      • Drugs approved for the treatment of obesity
      • Cypropheptadine or medroxyprogesterone
      • Atypical anti-psychotic drugs
      • Tricyclic antidepressants
      • Lithium, MAO's,
      • SSRI's or SNRI's
      • Antiepileptic drugs
      • Systemic corticosteroids
      • Stimulants e.g. amphetamines
    12. Any dietary supplement that is labeled for weight management or maintenance of healthy weight
  5. Diagnosis or evidence of eating disorders
  6. ≥ 5% weight change in the last 3 months
  7. Subjects who have had bariatric surgery
  8. An infection requiring antibiotic treatment within the last 30 days
  9. Any chronic inflammatory disease, e.g. inflammatory bowel disease rheumatoid arthritis, vasculitis, systemic lupus erythematosus
  10. Diseases interfering with metabolism (including metabolism of branched chain amino acids) and/or ingestive behavior (myxedema, Cushing's disease, diabetes, schizophrenia, major psychoses, maple syrup urine disease, unmanaged depression etc.)
  11. History of alcohol abuse (defined ≥ 21 drinks per week for males and > 14 drinks per week for females), within the past 3 months or failure on urinary drug screen
  12. History of substance abuse (including alcohol abuse as defined above) in the past 12 months or a positive screen for drugs (opioids without a prescription), including marijuana, of abuse or alcohol at screening.
  13. Has received any drug within 3 months of Screening.
  14. Has donated blood within 3 months before Screening or is planning to donate blood during the study (due to HbA1c reading at screening)
  15. Other medical conditions that may diminish to \<2 years, including known cancers
  16. Have been diagnosed with carcinomas in the last 5 years
  17. Has known allergies or to metformin, sildenafil or leucine
  18. Have suffered myocardial infarction, stroke, arrhythmia in the last 6 months
  19. Resting hypotension (BP \<90/50 mmHg) or severe hypertension (BP >170/110 mmHg) If both or one of the parameters for diastolic or systolic BP is meet
  20. Cardiac failure or coronary artery disease causing unstable angina
  21. History or evidence at screening of left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure
  22. At risk for priapism due to anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie's disease) or other conditions that predispose to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia)
  23. Clinical evidence of hepatic impairment and/or /AST >5X
  24. Is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or NuSirt Biopharma.
  25. Is employed by NuSirt Biopharma (defined as an employee, temporary contract worker, or designee responsible for the conduct of the study).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Each dose of placebo will consist of three tablets, identical in appearance to those used in the two active treatment arms, containing 93.5% Microcrystalline cellulose PH 102, 5.0% Crospovidone XL 10, 1.0% Silica gel (Syloid 244), 0.5% Magnesium stearate I MF3V for the leucine matched placebo and 99.5% Avicel PH200 , 0.5% magnesium stearate (w/w) and Opadry II White coating 3% weight gain for the sildenafil matched placebo.

    Drug: Placebo

  • Experimental
    Leu Sil 1.0mg

    3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 1.0 mg of sildenafil

    Drug: Leu Sil 1.0mg · Drug: Leu Sil 4.0mg

  • Experimental
    Leu Sil 4.0mg

    3 capsules BID consisting of 2 capsules containing 550 mg L-leucine each and 1 capsule containing 4.0 mg of sildenafil

    Drug: Leu Sil 1.0mg · Drug: Leu Met Sil 1.0mg

  • Experimental
    Leu Met Sil 1.0mg

    3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 1.0 mg of sildenafil

    Drug: Leu Sil 1.0mg · Drug: Leu Sil 4.0mg · Drug: Leu Met Sil 4.0mg

  • Experimental
    Leu Met Sil 4.0mg

    3 capsules BID consisting of 2 capsules containing 550 mg L-leucine and 250 mg metformin and 1 capsule containing 4.0 mg of sildenafil

    Drug: Leu Sil 1.0mg · Drug: Leu Met Sil 1.0mg · Drug: Leu Met Sil 4.0mg

Interventions

  • DrugLeu Sil 1.0mg

    Leu 1100 mg + 1mg Sil BID

    Also known as: NS-0300-1.0

  • DrugLeu Sil 4.0mg

    Leu 1100 mg + 4mg Sil BID

    Also known as: NS-0300-4.0

  • DrugLeu Met Sil 1.0mg

    Leu 1100 mg + Met 500mg + 1mg Sil BID

    Also known as: NS-0200-1.0

  • DrugLeu Met Sil 4.0mg

    Leu 1100 mg + Met 500mg + 4mg Sil BID

    Also known as: NS-0200-4.0

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage Body Weight Change

    The percentage body weight change from baseline to Day 168 was evaluated.

    Time frame: Baseline to Day 168

Secondary outcomes

  1. Change in Absolute Body Weight

    The change in absolute body weight from baseline to day 168 was evaluated.

    Time frame: Baseline to Day 168

  2. Change in Percentage of Patients With ≥5% Body Weight Loss

    The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.

    Time frame: Baseline to Day 168

  3. Change in Waist Circumference

    The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.

    Time frame: Baseline to Day 168

  4. Change in Total Cholesterol

    Changes in total cholesterol was examined by standard blood chemistry.

    Time frame: Baseline to Day 168

  5. Change in HDL Cholesterol

    Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.

    Time frame: Baseline, Day 168

  6. Change in LDL Cholesterol

    Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.

    Time frame: Baseline, 168 days

  7. Change in Triglycerides

    The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.

    Time frame: Baseline, Day 168

  8. Change in Plasma Glucose

    Change in plasma glucose was examined through standard fasting blood chemistry.

    Time frame: Baseline to Day 168

  9. Change in Hemoglobin A1c (HbA1c)

    Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.

    Time frame: Baseline, Day 168

  10. Change in Diastolic Blood Pressure

    Diastolic blood pressure was measured by standard blood pressure monitor.

    Time frame: Baseline to Day 168

  11. Change in Systolic Blood Pressure

    Change in Systolic blood pressure was assessed in patients from baseline to Day 168

    Time frame: Baseline, Day 168

  12. Change in Inflammatory Markers

    hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry.

    Time frame: Baseline to Day 168

07

Results

Posted Nov 27, 2018

Participant flow

Subjects meeting all inclusion criteria and no exclusion criteria were randomized to one of five treatment arms in the ratio of 1:1:1:1:1(A:B:C:D:E). The randomization was stratified by a maximum of 70% female with a BMI range between 30 kg/m2 and 45 kg/m2

Participant flow — Overall Study
MilestonePlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Started5251535052
Completed4240423741
Not completed1011111311
Withdrew: Adverse event34120
Withdrew: Lost to follow-up77101111

Outcome measures

PrimaryPercentage Body Weight Change

The percentage body weight change from baseline to Day 168 was evaluated.

Time frame:
Baseline to Day 168
Reported as:
Mean · percentage
Percentage Body Weight Change
percentagePlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Percentage Body Weight Change1.121 ± 3.62410.674 ± 3.2286-0.489 ± 3.9041-0.929 ± 4.5533-0.552 ± 2.5924
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.5461
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.0364
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.0156
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.0349
SecondaryChange in Absolute Body Weight

The change in absolute body weight from baseline to day 168 was evaluated.

Time frame:
Baseline to Day 168
Reported as:
Mean · kg
Change in Absolute Body Weight
kgPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Absolute Body Weight1.126 ± 3.59030.678 ± 3.2502-0.460 ± 4.0352-0.870 ± 4.5445-0.461 ± 2.7583
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.5348
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.0379
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.0215
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.0464
SecondaryChange in Percentage of Patients With ≥5% Body Weight Loss

The number of patients with ≥5% body weight loss in each group was assessed from baseline to day 168.

Time frame:
Baseline to Day 168
Reported as:
Count of participants · Participants
Change in Percentage of Patients With ≥5% Body Weight Loss
ParticipantsPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Percentage of Patients With ≥5% Body Weight Loss21673
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · Chi-squared · p = 1.0000
  • Placebo vs Leu Sil 4.0mg · Chi-squared · p = 0.2646
  • Placebo vs Leu Met Sil 1.0mg · Chi-squared · p = 0.0749
  • Placebo vs Leu Met Sil 4.0mg · Chi-squared · p = 0.6758
SecondaryChange in Waist Circumference

The change in waist circumference by using a tape measure across the mid-section was evaluated in subjects from baseline to day 168.

Time frame:
Baseline to Day 168
Reported as:
Mean · cm
Change in Waist Circumference
cmPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Waist Circumference0.043 ± 5.55910.028 ± 5.5152-1.060 ± 5.5564-1.841 ± 4.76540.637 ± 5.7908
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.9656
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.4254
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.1276
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.5937
SecondaryChange in Total Cholesterol

Changes in total cholesterol was examined by standard blood chemistry.

Time frame:
Baseline to Day 168
Reported as:
Mean · mg/dL
Change in Total Cholesterol
mg/dLPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Total Cholesterol1.0 ± 20.330.2 ± 20.961.9 ± 20.01-0.7 ± 16.74-6.6 ± 23.48
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.6010
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.6513
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.4354
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.0310
SecondaryChange in HDL Cholesterol

Changes were measured in HDL cholesterol from Baseline to day 168 by standard blood chemistry.

Time frame:
Baseline, Day 168
Reported as:
Mean · mg/dL
Change in HDL Cholesterol
mg/dLPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in HDL Cholesterol1.1 ± 7.430.6 ± 7.592.4 ± 6.401.8 ± 8.211.6 ± 7.72
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.4644
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.8573
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.8167
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.9223
SecondaryChange in LDL Cholesterol

Changes in LDL Cholesterol was measured by standard blood chemistry from baseline to day 168.

Time frame:
Baseline, 168 days
Reported as:
Mean · mg/dL
Change in LDL Cholesterol
mg/dLPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in LDL Cholesterol-5.5 ± 15.40-6.6 ± 16.86-4.2 ± 15.81-5.5 ± 11.77-11.6 ± 19.72
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.6574
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.8971
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.6317
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.0341
SecondaryChange in Triglycerides

The change in triglycerides was evaluated by standard blood chemistry in subjects from Baseline to Day 168.

Time frame:
Baseline, Day 168
Reported as:
Mean · mg/dL
Change in Triglycerides
mg/dLPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Triglycerides13.4 ± 45.439.7 ± 56.421.9 ± 51.93-4.4 ± 47.023.5 ± 52.03
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.3720
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.2302
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.1377
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.4295
SecondaryChange in Plasma Glucose

Change in plasma glucose was examined through standard fasting blood chemistry.

Time frame:
Baseline to Day 168
Reported as:
Mean · mg/dL
Change in Plasma Glucose
mg/dLPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Plasma Glucose0.4 ± 7.98-1.6 ± 9.350.3 ± 9.591.1 ± 12.43-1.7 ± 10.87
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.6726
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.7934
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.5485
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.3676
SecondaryChange in Hemoglobin A1c (HbA1c)

Change in Hemoglobin A1c was assessed in the subjects from baseline to day 168.

Time frame:
Baseline, Day 168
Reported as:
Mean · percentage of glycosylated hemoglobin
Change in Hemoglobin A1c (HbA1c)
percentage of glycosylated hemoglobinPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Hemoglobin A1c (HbA1c)0.16 ± 0.1640.09 ± 0.1670.11 ± 0.1650.07 ± 0.1980.09 ± 0.177
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.1653
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.1970
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.0608
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.1583
SecondaryChange in Diastolic Blood Pressure

Diastolic blood pressure was measured by standard blood pressure monitor.

Time frame:
Baseline to Day 168
Reported as:
Mean · mmHg
Change in Diastolic Blood Pressure
mmHgPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Diastolic Blood Pressure-1.7 ± 7.131.8 ± 9.57-2.6 ± 8.101.1 ± 9.16-3.3 ± 7.48
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.0524
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.5221
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.3702
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.5426
SecondaryChange in Systolic Blood Pressure

Change in Systolic blood pressure was assessed in patients from baseline to Day 168

Time frame:
Baseline, Day 168
Reported as:
Mean · mmHg
Change in Systolic Blood Pressure
mmHgPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Systolic Blood Pressure-2.0 ± 9.970.5 ± 12.21-2.7 ± 9.120.6 ± 9.31-3.5 ± 9.29
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.1843
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.4411
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.6991
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.3721
SecondaryChange in Inflammatory Markers

hs-C-Reactive Protein (CRP) levels was examined by standard blood chemistry.

Time frame:
Baseline to Day 168
Reported as:
Mean · mg/L
Change in Inflammatory Markers
mg/LPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Change in Inflammatory Markers0.90 ± 2.4010.12 ± 3.6330.35 ± 3.3850.56 ± 6.6240.12 ± 3.551
Statistical analysis
  • Placebo vs Leu Sil 1.0mg · ANCOVA · p = 0.0318
  • Placebo vs Leu Sil 4.0mg · ANCOVA · p = 0.3827
  • Placebo vs Leu Met Sil 1.0mg · ANCOVA · p = 0.0050
  • Placebo vs Leu Met Sil 4.0mg · ANCOVA · p = 0.1045

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/52 (0%)0/52 (0%)14/52 (26.9%)
Leu Sil 1.0mg0/51 (0%)2/51 (3.9%)19/51 (37.3%)
Leu Sil 4.0mg0/53 (0%)0/53 (0%)12/53 (22.6%)
Leu Met Sil 1.0mg0/50 (0%)1/50 (2%)21/50 (42%)
Leu Met Sil 4.0mg0/52 (0%)0/52 (0%)19/52 (36.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
Metastatic malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/520/510/531/500/52
Tooth abscessInfections and infestations0/521/510/530/500/52
HypokalaemiaMetabolism and nutrition disorders0/521/510/530/500/52
Anal CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/521/510/530/500/52
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mg
DiarrhoeaRenal and urinary disorders1/522/514/5321/5012/52
HeadacheGeneral disorders4/526/510/534/505/52
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders5/526/512/534/504/52
NauseaGeneral disorders1/524/511/534/506/52
NasopharyngitisGeneral disorders1/525/510/531/502/52
ArthralgiaMusculoskeletal and connective tissue disorders0/524/510/530/500/52
Increased AppetiteGeneral disorders2/524/512/532/503/52
SinusitisGeneral disorders1/520/510/530/504/52
Abdominal PainGastrointestinal disorders1/520/511/533/501/52
Back PainMusculoskeletal and connective tissue disorders0/520/511/533/501/52

Baseline characteristics

Subjects who met the inclusion criteria, with BMI between 30kg/m2 and 45kg/m2.

Age, Categorical
Age, Categorical(Participants)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
<=18 years000000
Between 18 and 65 years5251535052258
>=65 years000000
Age, Continuous
Age, Continuous(years)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
Mean41.29 ± 11.3040.94 ± 11.1439.55 ± 11.1441.36 ± 12.6642.89 ± 10.7041.20 ± 11.36
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
Female3829323935173
Male142221111785
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
Hispanic or Latino81213121560
Not Hispanic or Latino4439403837198
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
American Indian or Alaska Native100001
Asian001214
Native Hawaiian or Other Pacific Islander000000
Black or African American9913111153
White4042393740198
More than one race000000
Unknown or Not Reported200002
Weight (kg)
Weight (kg)(kg)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
Mean101.67 ± 13.856105.05 ± 15.568107.16 ± 17.962100.18 ± 16.991104.50 ± 17.405103.74 ± 16.49
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
Mean35.773 ± 3.3137.179 ± 4.2837.9 ± 4.2036.425 ± 4.1337.152 ± 4.2336.89 ± 4.08
Waist Circumference
Waist Circumference(cm)PlaceboLeu Sil 1.0mgLeu Sil 4.0mgLeu Met Sil 1.0mgLeu Met Sil 4.0mgTotal
Mean110.40 ± 10.998112.91 ± 11.466116.02 ± 12.411111.17 ± 13.291112.93 ± 13.311112.71 ± 12.39
08

Study locations

15 sites
  • AMR
    Mobile, Alabama 36608, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • ACR
    Meridian, Idaho 83642, United States
  • Synexus
    Chicago, Illinois 60602, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Clinical Trials Management
    Metairie, Louisiana 70006, United States
  • Synexus
    Saint Louis, Missouri 63141, United States
  • AMR
    Las Vegas, Nevada 89119, United States
  • Rapid Medical Research
    Cleveland, Ohio 44122, United States
  • Medical Research South
    Charleston, South Carolina 29407, United States
  • Premier
    Clarksville, Tennessee 37040, United States
  • Synexus
    Dallas, Texas 75234, United States
  • Synexus
    San Antonio, Texas 78229, United States
  • ACR
    Jordan, Utah 84088, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Aug 2018, 6 months.

Results were first posted in Nov 2018, 3 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 6 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2017
First posted
Dec 6, 2017
StartActual
Jan 8, 2018
Primary completionActual
Aug 6, 2018
CompletionActual
Aug 17, 2018
Results first posted
Nov 27, 2018
Last update
Aug 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03364335
Lead sponsor
NuSirt Biopharma
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Jan 8, 2018
Primary completion
Aug 6, 2018
Completion
Aug 17, 2018
Results posted
Nov 27, 2018
Last update
Aug 21, 2019

Study contacts

Michael B Zemel, PhD
study chair · NuSirt Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion